Microbiotix

About Microbiotix

Microbiotix is a clinical-stage biopharmaceutical company focused on developing proprietary small molecule drugs to treat serious infectious diseases, including those caused by multi-drug resistant pathogens. Founded in 1998 and headquartered in Worcester, Massachusetts, the company has built a reputation for its work in the anti-infective space. The leadership team includes President & CEO Terry L. Bowlin, PhD, who has over three decades of experience in anti-infective research and drug development.

The company's business model centers on the discovery and development of novel therapeutics. Microbiotix has been a consistent recipient of NIH awards, which supplement its funding. Its primary clients are patients suffering from severe viral and bacterial infections, particularly in settings like organ transplantation and hospital-acquired infections. The company collaborates with various partners and has received significant non-dilutive funding from organizations like CARB-X to advance its pipeline.

Microbiotix's lead product candidate is MBX-400 (filociclovir), a novel nucleoside analog inhibitor for cytomegalovirus (CMV) infections, which commonly affect immunosuppressed transplant recipients. MBX-400 has a unique dual mechanism of action, targeting both DNA polymerase and UL97 kinase, and has demonstrated greater potency than standard therapies in preclinical studies. It has successfully completed Phase 1 clinical trials. The company is also developing an ophthalmic formulation of MBX-400 for adenoviral conjunctivitis, a common cause of eye infections with no currently approved antiviral therapy. Beyond MBX-400, Microbiotix's pipeline includes a program funded by CARB-X to develop a new oral antibiotic for multi-drug resistant gonorrhea and novel spectinamide antibiotics to treat multi-drug-resistant tuberculosis.